Hepatic Angiosarcoma

Back to news list

Source: NEJM

Original: https://www.nejm.org/doi/full/10.1056/NEJMicm2514897?af=R&rss=currentIssue...

Published: 2026-02-07T12:30:00Z

Hepatic angiosarcoma (PHA) accounts for only 2–3% of soft tissue sarcomas in adults and has a poor prognosis.[1] It is a very rare tumor associated mainly with exposure to vinyl chloride, although the cause is unknown in most patients.[1][3] It often affects the liver multifocally, can cause noncirrhotic portal hypertension, and requires pathohistological diagnosis because specific symptoms are lacking.[1][2] Median survival is 5 months, while local excision with adjuvant therapy reaches 17 months.[1] Liver transplantation is not recommended due to high recurrence rate.[1][2] Transcatheter arterial chemoembolization, chemotherapy, or embolization are useful for controlling bleeding and prolonging survival.[1][2] Additional cases of angiosarcoma and portal fibrosis were found in one program in vinyl chloride workers.[3]